Beyond Air

Client

Beyond Air

Year

2015-Present

Services

Device Development - Clinical, Vendor Management, Device Development - Preclinical, Device Development - Regulatory, Device Development - Start-up

Field

Devices

Challenge

Scaling and growing a small start up company to a NASDAQ listed company with promising and near commercial pipeline.

“Novateur’s vast and knowledgeable advisors have been instrumental in enabling our success in development and commercialization of our pipeline and our recent IPO. We highly recommend them.”

Amir Avniel
Co-Founder, COO & President, Beyond Air

image

From a small startup company to NASDAQ in 4 years

Beyond’s Air engagement with Novateur Ventures began in 2015 (when Beyond Air was known as AIT Therapeutics). Novateur was engaged in 2015 to assist in designing and building a new device for Beyond Air’s trials. The engagement was expanded to developing Target Product Profiles and clinical development plans. This engagement was further expanded in 2016 when Novateur Advisor, Steve Lisi joined AIT Therapeutics as their Chairman and CEO and led successful fundraising efforts, RTO in 2017 and NASDAQ uplisting in 2019. Throughout the engagement, Novateur Business Development team sourced the leading Nitric Oxide platform technology for Beyond Air, which was in-licensed in 2017. The Novateur team also managed regulatory affairs, toxicology and FDA interactions. 

Over the past 5 years, our advisory team became part of Beyond Air team and worked seamlessly. Several advisors are now executives at Beyond Air. We are very proud to see Beyond Air’s success.

 

Learn more about Beyond Air

Beyond Air press releases

 

Novateur
Newsletter

Subscribe to our newsletter for access to latest updates.

Resource
Databases

Access Novateur news as well as FDA and Expert Databases.

Relevant
Events

Check out conferences and events we are attending!

Article
Features

Read articles by our team! Featured in BioteCanada Insights and Nature among others.